Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Early Intervention Important for Sunitinib-Related Hypertension in RCC

November 26, 2016
By Leah Lawrence
Article

Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.

Patients with metastatic renal cell carcinoma (RCC) treated with sunitinib often experience treatment-related hypertension (tHTN). A retrospective study published recently in Clinical Genitourinary Cancer showed that these patients require rigorous blood pressure control and that the use of calcium channel blockers was best for controlling hypertension compared with other antihypertensive drugs.  

“Early intervention for tHTN might be important when blood pressure increases above the threshold of 140/90 mm Hg,” wrote researcher Philipp Ivanyi, MD, of Hanover Medical School, Germany, and colleagues. “In the absence of confounding factors (such as congestive heart failure), nondihydropyridine calcium channel blocker is the best way to quickly and reliably control tHTN.”

Sunitinib works by inhibiting the vascular endothelial growth factor (VEGF). In tumor cells, this signal inhibits tumor vasculature; however, in healthy cells it is associated with tHTN. Previous studies have shown a risk for hypertension among patients treated with VEGF receptor inhibitors and sunitinib, but because cardiovascular risk factors are common in patients with metastatic RCC, Ivanyi and colleagues wanted to explore the occurrence of this adverse event further.

They conducted a retrospective study of 72 patients with metastatic RCC treated with sunitinib from June 2004 to December 2011. They examined their medical records for risk factors for tHTN and antihypertensive treatments.

A little more than 70% of patients in the study developed tHTN after a median of 28 days on sunitinib. The mean blood pressure increased from 130/75 mm Hg on day 1 to 140/80 mm Hg on day 28. Only patients with tHTN had significant increases in blood pressure while on sunitinib.

The researchers found that a standard dose of sunitinib, age older than 50 years, and prehypertension were all independent risk factors for developing tHTN.

Antihypertensive therapies significantly reduced blood pressure among patients with tHTN. Among the patients diagnosed with tHTN, 70.8% received some kind of antihypertensive treatment and 72.5% received at last one modification of the antihypertension therapy at a median of 3 days after detection of tHTN. Calcium channel blockers were significantly better at controlling tHTN compared with other drugs (P = .045).

The researchers said that the results of this study should be interpreted with caution.

“In particular, the predominantly administered calcium channel blocker might cause an overestimation of its true efficacy in our statistical model,” they wrote. In addition, within the study period there were patients lost to follow-up or incomplete medical records.

Routine and permanent blood pressure monitoring should be considered in patients at high risk of tHTN, the researchers wrote, including patients older than 50 years of age, with pre-hypertension, or with a once daily sunitinib starting dose of 50 mg. “If control of tHTN is inadequate, an early combination of agents with different mechanisms of action may provide better control of tHTN.”

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Related Content
Advertisement

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.

FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset

Tim Cortese
October 22nd 2025
Article

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC

Chris Ryan
October 19th 2025
Article

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


Bladder cancer

Disitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer

Tim Cortese
October 19th 2025
Article

Disitamab vedotin plus toripalimab achieved a median 13.1-month PFS and median 31.5-month OS in patients with HER2-expressing advanced urothelial carcinoma.


At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.

Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

Tony Berberabe, MPH
October 19th 2025
Article

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.

Related Content
Advertisement

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.

FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset

Tim Cortese
October 22nd 2025
Article

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC

Chris Ryan
October 19th 2025
Article

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


Bladder cancer

Disitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer

Tim Cortese
October 19th 2025
Article

Disitamab vedotin plus toripalimab achieved a median 13.1-month PFS and median 31.5-month OS in patients with HER2-expressing advanced urothelial carcinoma.


At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.

Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

Tony Berberabe, MPH
October 19th 2025
Article

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.